Nebenwirkungen · Zilbrysq
Zilbrysq 16.6 mg solution for injection in pre-filled syringe Zilbrysq 23 mg solution for injection in pre-filled syringe Zilbrysq 32.4 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 5
HOS-147443 · Präparat HOS-099664
Table 2 presents the adverse reactions from the pooled placebo-controlled (n=115) and open-label extension (n=213) studies in gMG together with a classification of the frequency in the zilucoplan treated patients, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-21T10:00:00Z · SHA-256 ed25c5c08deebf114bc9f1f656d98e3eae28bdaef6471726525eeb9d21f69716 · Passage 48217c9539fa8a887c4adafd3b334dd1dd1e58c0b7c1211850487efc5862050d · Zeichen 339–884 im Abschnitt